Last reviewed · How we verify

NCT03397602: Exercise-AF

Exercise Training in Patients With Persistent or Permanent Atrial Fibrillation

Recruiting now NA Last updated 11 March 2026
What this trial tests

NA trial testing standard care + moderate-intensity continuous exercise training in Atrial Fibrillation in 132 participants. Currently enrolling.

Timeline
23 January 2019
Primary endpoint
30 December 2027
30 December 2037

Quick facts

Lead sponsorOttawa Heart Institute Research Corporation
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment132
Start date23 January 2019
Primary completion30 December 2027
Estimated completion30 December 2037
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Ottawa Heart Institute Research Corporation

Who can join

40 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this project is to evaluate the effects of high-intensity interval training (HIIT) compared to moderate-intensity continuous exercise training (MICE) and standard care on exercise capacity and quality of life in patients with persistent or permanent atrial fibrillation. Positive findings are vitally important for these patients, given the condition's substantial morbidity, mortality and high economic costs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Ottawa Heart Institute Research Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03397602.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing